Is the risk of brain metastasis and prognosis different in HER2-low breast cancer?
3/5 보강
TL;DR
The distinct MYC gene amplification patterns in the concurrent angiosarcoma and carcinoma reflect the complexity of the MYC gene in the tumorigenesis of different types of malignancies and may explain the different levels of MYC protein expression on immunohistochemistry.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
2 cases, are notable limitations.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Recurrence with brain metastasis and general disease recurrence were more common in the HR(-) HER2-low group. The study's retrospective design and the limited number of patients, especially in the HR(-) HER2-low group, along with potential underreporting in 1 + HER2 cases, are notable limitations.
OpenAlex 토픽 ·
Brain Metastases and Treatment
HER2/EGFR in Cancer Research
Lung Cancer Treatments and Mutations
The distinct MYC gene amplification patterns in the concurrent angiosarcoma and carcinoma reflect the complexity of the MYC gene in the tumorigenesis of different types of malignancies and may explain
- p-value p = 0.001
- p-value p < 0.001
- 95% CI 6.70-156.2
- OR 12.4
- HR 32.82
- 추적기간 56.6 months
APA
Yaşar Çulha, Beyza Ünlü, et al. (2026). Is the risk of brain metastasis and prognosis different in HER2-low breast cancer?. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 28(5), 1624-1636. https://doi.org/10.1007/s12094-025-04106-6
MLA
Yaşar Çulha, et al.. "Is the risk of brain metastasis and prognosis different in HER2-low breast cancer?." Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol. 28, no. 5, 2026, pp. 1624-1636.
PMID
41222828 ↗
Abstract 한글 요약
[PURPOSE] We aimed to evaluate whether brain metastases, which are one of the most critical factors that have a poor prognostic value and make treatment difficult in breast cancer cases, differ in HER2-low breast cancer and to evaluate the prognosis of HER2-low breast cancer.
[METHOD] This retrospective study included 1134 female patients diagnosed with breast cancer between June 2012 and June 2023 from two tertiary healthcare centers in Türkiye. Molecular groups were examined in six categories according to hormone receptor (HR) and human epidermal growth factor receptor (HER2) status (HR(+) HER2(-), HR(+) HER2-low, HR(+) HER2(+), HR(-) HER2(-), HR(-) HER2-low, and HR(-) HER2(+)).
[RESULTS] The median follow-up period was 56.6 months (IQR 29.9-90.5). We detected HER2-low disease in 155 (13.7%) cases. Among the six molecular groups, the highest brain metastasis rate was observed in the HR(-) HER2-low group (22.2%) (p = 0.001). In the HR(+) HER2-low group, the brain metastasis rate was 3.8%, with no statistically significant difference (p = 0.13). In the multivariate binary logistic regression model, there was a 32.4-fold increase in the risk of brain metastasis for the HR(-) HER2-low group compared to the HR(+) HER2(-) group (OR: 12.4, 95% CI 6.70-156.2, p < 0.001). The analysis reveals no significant increase in risk for the HR(+) HER2-low group (OR: 1.68, CI: 0.42-6.67, p = 0.46). In the Cox's regression model, the highest risk for poor BMFS was found in the HR(-) HER2-low group compared to the HR(+) HER2(-) group, with a 32.8-fold increased risk (HR: 32.82, CI: 7.80-138.3, p < 0.001). In the Cox's regression model, the highest risk for poor DFS was detected in the HR(-) HER2-low group compared to the HR(+) HER2(-) group, with a fourfold increase in risk (HR: 4.05, CI 1.34-12.30, p = 0.013). Shorter BMSS times were observed in the triple-negative and HR(-) HER2-low groups (1.33 and 3.9 months, respectively; p = 0.001).
[CONCLUSION] Our study found that the risk of brain metastasis and disease recurrence increased significantly in the HR(-) HER2-low group, and contrary to some literature data, the risk of brain metastasis in the HR(+) HER2-low group did not differ from the HR(+) HER2(-) group. Both in our study and in many existing studies in the literature, it seems that the HR(+) HER2-low group has a similar prognosis with the HR(+) HER2(-) group, and the HR(-) HER2-low group is in an intermediate form between the HR(-) HER2(+) and HR(-) HER2(-) groups. Recurrence with brain metastasis and general disease recurrence were more common in the HR(-) HER2-low group. The study's retrospective design and the limited number of patients, especially in the HR(-) HER2-low group, along with potential underreporting in 1 + HER2 cases, are notable limitations.
[METHOD] This retrospective study included 1134 female patients diagnosed with breast cancer between June 2012 and June 2023 from two tertiary healthcare centers in Türkiye. Molecular groups were examined in six categories according to hormone receptor (HR) and human epidermal growth factor receptor (HER2) status (HR(+) HER2(-), HR(+) HER2-low, HR(+) HER2(+), HR(-) HER2(-), HR(-) HER2-low, and HR(-) HER2(+)).
[RESULTS] The median follow-up period was 56.6 months (IQR 29.9-90.5). We detected HER2-low disease in 155 (13.7%) cases. Among the six molecular groups, the highest brain metastasis rate was observed in the HR(-) HER2-low group (22.2%) (p = 0.001). In the HR(+) HER2-low group, the brain metastasis rate was 3.8%, with no statistically significant difference (p = 0.13). In the multivariate binary logistic regression model, there was a 32.4-fold increase in the risk of brain metastasis for the HR(-) HER2-low group compared to the HR(+) HER2(-) group (OR: 12.4, 95% CI 6.70-156.2, p < 0.001). The analysis reveals no significant increase in risk for the HR(+) HER2-low group (OR: 1.68, CI: 0.42-6.67, p = 0.46). In the Cox's regression model, the highest risk for poor BMFS was found in the HR(-) HER2-low group compared to the HR(+) HER2(-) group, with a 32.8-fold increased risk (HR: 32.82, CI: 7.80-138.3, p < 0.001). In the Cox's regression model, the highest risk for poor DFS was detected in the HR(-) HER2-low group compared to the HR(+) HER2(-) group, with a fourfold increase in risk (HR: 4.05, CI 1.34-12.30, p = 0.013). Shorter BMSS times were observed in the triple-negative and HR(-) HER2-low groups (1.33 and 3.9 months, respectively; p = 0.001).
[CONCLUSION] Our study found that the risk of brain metastasis and disease recurrence increased significantly in the HR(-) HER2-low group, and contrary to some literature data, the risk of brain metastasis in the HR(+) HER2-low group did not differ from the HR(+) HER2(-) group. Both in our study and in many existing studies in the literature, it seems that the HR(+) HER2-low group has a similar prognosis with the HR(+) HER2(-) group, and the HR(-) HER2-low group is in an intermediate form between the HR(-) HER2(+) and HR(-) HER2(-) groups. Recurrence with brain metastasis and general disease recurrence were more common in the HR(-) HER2-low group. The study's retrospective design and the limited number of patients, especially in the HR(-) HER2-low group, along with potential underreporting in 1 + HER2 cases, are notable limitations.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.